4:33 PM
 | 
Sep 25, 2017
 |  BC Extra  |  Clinical News

Daiichi planning Japanese application for hypertension candidate

Daiichi Sankyo Co. Ltd. (Tokyo:4568) and Exelixis Inc. (NASDAQ:EXEL) said esaxerenone (CS-3150) met the primary endpoint in the Japanese Phase III ESAX-HTN trial to treat essential hypertension. In 1Q18, Daiichi plans to submit a regulatory application...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >